Aerie Pharmaceuticals Inc Income
What is the Income of Aerie Pharmaceuticals Inc?
The Income of Aerie Pharmaceuticals Inc is -$36.56
What is the definition of Income?
Net income available for common shareholders equals net income minus preferred dividends paid.
ttm (trailing twelve months)
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
Income of companies in the Health Care sector on NASDAQ compared to Aerie Pharmaceuticals Inc
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Companies with income similar to Aerie Pharmaceuticals Inc
- Twintek Investment has Income of -HKD$36.72
- Simplicity has Income of -HKD$36.69
- Mack-Cali Realty has Income of -$36.65
- SPI Co Ltd has Income of -$36.60
- Zelira Therapeutics has Income of -AUD$36.58
- Thunder Bridge Acquisition II Ltd has Income of -$36.56
- Aerie Pharmaceuticals Inc has Income of -$36.56
- Eagle Bancorp Inc (MD) has Income of -$36.53
- Novan has Income of -$36.52
- Wai Chun has Income of -HKD$36.52
- BlackRock Debt Strategies Fund has Income of -$36.52
- Ontrak Inc has Income of -$36.52
- boohoo group Plc has Income of -£36.50